Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes

European Journal of Immunology

Volumn 37, Issue 9, 2007, Pages 2441-2449

  Stoloff, Gregory A ^a   Caparros Wanderley, Wilson ^a  

^a PepTcell Limited   (United Kingdom)

Author keywords

CD8 T Cells; Infectious diseases; Vaccination

Indexed keywords

EPITOPE; HLA A ANTIGEN; INFLUENZA VACCINE; SYNTHETIC PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CELLULAR IMMUNITY; COMPUTER MODEL; CONTROLLED STUDY; EPITOPE MAPPING; IMMUNIZATION; INFLUENZA; INFLUENZA VIRUS; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SEROTYPE; SURVIVAL; TRANSGENIC MOUSE; VIRUS STRAIN;

AMINO ACID SEQUENCE; ANIMALS; CELL LINE; COMPUTATIONAL BIOLOGY; EPITOPES, T-LYMPHOCYTE; HISTOCOMPATIBILITY ANTIGENS; HUMANS; INFLUENZA A VIRUS; INFLUENZA B VIRUS; INTERFERON TYPE II; MICE; MICE, INBRED C57BL; MOLECULAR SEQUENCE DATA; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDE FRAGMENTS; SEROTYPING; SURVIVAL RATE; T-LYMPHOCYTES; VIRAL PROTEINS;

EID: 34548711911     PISSN: 00142980     EISSN: None     Source Type: Journal    
DOI: 10.1002/eji.200737254     Document Type: Article

References (39)

1. Levy, E., French economic evaluations of influenza and influenza vaccination. Pharmacoeconomics 1996. 9(Suppl 3): 62-66.
2. Falsey, A. R., Cunningham, C. K., Barker, W. H., Kouides, R. W., Yuen, J. B., Menegus, M., Weiner, L. B. et al., Respiratory syncytial virus and influenza A infections in the hospitalized elderly. J. Infect. Dis. 1995. 172: 389-394.
3. Gerdil C., The annual production cycle for influenza vaccine. Vaccine 2003. 21: 1776-1779.
4. Bender, B. S., Croghan, T., Zhang, L. and Small, P. A. Jr., Transgenic mice lacking class I major histocompatibility complex-restricted T cells have delayed viral clearance and increased mortality after influenza virus challenge. J. Exp. Med. 1992. 175: 1143-1145.
5. Woodland, D. L., Cell-mediated immunity to respiratory virus infections. Curr. Opin. Immunol. 2003. 15: 430-435.
6. 8 T cells during primary pulmonary influenza virus infection. J. Immunol. 2005. 174: 5332-5340.
7. Graham, M. B. and Braciale, T. J., Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J. Exp. Med. 1997 186: 2063-2068.
8. Kast, W. M., Roux, L., Curren, J., Blom, H. J., Voordouw, A. C., Meloen, R. H., Kolakofsky, D. and Melief, C. J., Protection against lethal Sendai virus infection by in vivo priming of virus-specific cytotoxic T lymphocytes with a free synthetic peptide. Proc. Natl. Acad Sci. USA 1991. 88: 2283-2287
9. Aichele, P., Brduscha-Riem, K, Zinkernagel, R.M., Hengartner, H. and Pircher, H., T cell priming versus T cell tolerance induced by synthetic peptides. J. Exp. Med. 1995. 182: 261-266.
10. Nehete, P. N., Chitta, S., Hossain, M. M., Hill, L., Bernacky, B. J., Baze, W., Arlinghaus, R. B. and Sastry, K. J., Protection against chronic infection and AIDS by an HIV envelope peptide-cocktail vaccine in a pathogenic SHIV-rhesus model. Vaccine 2001. 20: 813-825.
11. + T-cell peptide epitope of vaccinia and variola viruses. J. Virol. 2004. 78: 7052-7060.
12. Le, A. X., Bernhard, E. J., Holterman, M. J., Strub, S., Parham, P., Lacy, E. and Engelhard, V. H., Cytotoxic T cell responses in HLA-A2.1 transgenic mice. Recognition of HLA alloantigens and utilization of HLA-A2.1 as a restriction element. J. Immunol. 1989. 142: 1366-1371.
13. Peachman, K. K., Rao, M., Alving, C. R., Palmer, D. R., Sun, W. and Rothwell, S. W., Human dendritic cells and macrophages exhibit different intracellular processing pathways for soluble and liposome-encapsulated antigens. Immunobiology 2005. 210: 321-333.
14. Thomas, P. G., Keating, R., Hulse-Post, D. J. and Doherty, P.C. Cell-mediated protection in influenza infection. Emerg. Infect. Dis. 2006. 12: 48-54.
15. Guthrie, T., Hobbs, C. G., Davenport, V., Horton, R. E., Heyderman, R. S. and Williams, N. A., Parenteral influenza vaccination influences mucosal and systemic T cell-mediated immunity in healthy adults. J. Infect. Dis. 2004. 190: 1927-1935.
16. Deng, Y., Jing, Y., Campbell, A. E. and Gravenstein, S. Age-related impaired type 1 T cell responses to influenza: Reduced activation ex vivo, decreased expansion in CTL culture in vitro, and blunted response to influenza vaccination in vivo in the elderly. J. Immunol. 2004. 172: 3437-3446.
17. He, X S., Holmes, T. H., Zhang, C., Mahmood, X, Kemble, G. W., Lewis, D. B., Dekker, C. L. et al., Cellular immune responses in children and adults receiving inactivated or live attenuated influenza vaccines. J. Virol. 2006. 80: 11756-11766.
18. De Jong, J. C., Rimmelzwaan, G. F., Fouchier, R. A. and Osterhaus, A. D., Influenza virus: A master of metamorphosis. J. Infect. 2000. 40: 218-228.
19. Hiromoto, Y., Yamazaki, Y., Fukushima, T., Saito, T., Lindstrom, S. E., Omoe, YL, Nerome, R. et al., Evolutionary characterization of the Six internal genes of H5N1 human influenza A virus. J. Gen. Virol. 2000. 81: 1293-1303.
20. Murphy, B. and Webster, R. Orthomyxoviruses. In: Fields, B., Knipe, D. and Howley, P. (Eds.) Virology. Lippincott-Raven, Philadelphia 1996, pp. 1397-1445.
21. Webster, R. G. The importance of animal influenza for human disease. Vaccine 2002. 20 (Suppl 2): S16-S20.
22. Tolle, T., Petry, H., Bachmann, B., Hunsmann, G. and Luke, W., Variability of the env gene in cynomolgus macaques persistently infected with human immunodeficiency virus type 2 strain ben. J. Virol.. 1994. 68: 2765-2771.
23. Caparros-Wanderley, W., Savage, N., Hill-Perkins, M., Layton, G., Weber, J. and Davies, D. H., Intratype sequence variation among clinical isolates of the human papillomavirus type 6 L1 ORF: Clustering of mutations and identification of a frequent amino acid sequence variant. J. Gen. Virol. 1999. 80: 1025-1033.
24. Xu, X., Cox, N. J., Bender, C. A., Regnery, H. L. and Shaw, M. W., Genetic variation in neuraminidase genes of influenza A (H3N2) viruses. Virology 1996. 224: 175-183.
25. Chi, X. S., Bolar, T. V., Zhao, P., Tam, J. S., Rappaport, R. and Cheng, S. M., Molecular evolution of human influenza A/H3N2 virus in Asia and Europe from 2001 to 2003. J. Clin. Microbiol. 2005. 43: 6130-6132.
26. Kawaoka, Y., Krauss, S. and Webster, R. G., Avian-to-human transmission of the PB1 gene of influenza A viruses in the 1957 and 1968 pandemics. J. Virol. 1989. 63: 4603-4608.
27. Nerome, K., Kanegae, Y., Shortridge, YL F., Sugita, S. and Ishida, M., Genetic analysis of porcine H3N2 viruses originating in southern China. J. Gen. Virol. 1995. 76: 613-624.
28. Flower, D. R., Towards in silico prediction of immunogenic epitopes. Trends Immunol. 2003. 24: 667-674.
29. Deavin, A. J., Auton, T. R. and Greaney, P. J., Statistical comparison of established T-cell epitope predictors against a large database of human and murine antigens. Mol. Immunol. 1996. 33: 145-155.
30. Sette, A., Vitiello, A., Reherman, B., Fowler, P., Nayersina, R., Kast, W. M., Melief, C. J. et al., The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes. J. Immunol. 1994. 153: 5586-5592.
31. Brander, C., O'Connor, P., Suscovich, T., Jones, N. G., Lee, Y., Kedes, D., Ganem, D. et al., Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J. Infect. Dis. 2001. 184: 119-126.
32. Andersen, M. H., Tan, L., Sondergaard, I., Zeuthen, J., Elliott, T. and Haurum, J. S., Poor correspondence between predicted and experimental binding of peptides to class I MHC molecules. Tissue Antigens 2000. 55: 519-531.
33. Yewdell, J. W. and Bennink, J. R., Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu. Rev. Immunol. 1999. 17: 51-88.
34. + memory T cells specific for a subdominant epitope following Sendai virus infection. J. Immunol. 1997. 158: 4301-4309.
35. Oukka, M., Manuguerra, J. C., Livaditis, N., Tourdot, S., Riche, N., Vergnon, I., Cordopatis, P. and Kosmatopoulos, K., Protection against lethal viral infection by vaccination with nonimmunodominant peptides. J. Immunol. 1996. 157: 3039-3045.
36. Rammensee, H. G., Some considerations on the use of peptides and mRNA for therapeutic vaccination against cancer. Immunol. Cell Biol. 2006. 84: 290-294.
37. Ward, S., Casey, D., Labarthe, M. C., Whelan, M., Dalgleish, A., Pandha, H. and Todryk, S., Immunotherapeutic potential of whole tumour cells. Cancer Immunol. Immunother. 2002. 51: 351-357.
38. Chenna, R., Sugawara, H, Koike, T., Lopez, R., Gibson, T. J., Higgins, D. G. and Thompson, J. D., Multiple sequence alignment with the Clustal series of programs. Nucleic Acids Res. 2003. 31: 3497-3500.
39. Shirai, M., Arichi, T., Nishioka, M., Nomura, T., Ekeda, K., Kawanishi, K,, Engelhard, V. H. et al., CTL responses of HLA-A2.1 -transgenic mice specific for hepatitis C viral peptides predict epitopes for CTL of humans carrying HLA-A2.1. J. Immunol. 1995. 154: 2733-2742.